| http://dbpedia.org/ontology/abstract
|
TiGenix is a European cell therapy company … TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University. TiGenix's therapeutic approach is to focus on the use of living cells rather than conventional drugs for the treatment of inflammatory and autoimmune diseases, through its eASC-based platform, and heart disease, through its CSC-based platform. TiGenix's pipeline of stem cell programs is based on validated platforms of allogeneic stem cells.idated platforms of allogeneic stem cells.
|
| http://dbpedia.org/ontology/foundingYear
|
2000
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/Eduardo_Bravo +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/Leuven +
, http://dbpedia.org/resource/Belgium +
|
| http://dbpedia.org/ontology/numberOfEmployees
|
70
|
| http://dbpedia.org/ontology/type
|
http://www.euronext.com/trader/summarizedmarket/stocks-2593-EN-BE0003864817.html%3Bjsessionid=FD54125A866BCE438B0AF76FB369FA1F.373B37E822206BE62D2C2EBB70%3FselectedMep=3 +
, http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.euronext.com/trader/summarizedmarket/stocks-2593-EN-BE0003864817.html%3Bjsessionid=FD54125A866BCE438B0AF76FB369FA1F.373B37E822206BE62D2C2EBB70%3FselectedMep=3 +
, http://www.tigenix.com/ +
, http://www.lecho.be/entreprises/pharma_biotechnologie/La_commercialisation_du_Cx601_pourrait_demarrer_en_2017_dans_l_Union_europeenne.9520057-3002.art%3Fhighlight=cx601/ +
, http://www.tijd.be/detail.art%3Fa=9501373&n=3070&ckc=1/ +
, http://www.tigenix.com +
|
| http://dbpedia.org/ontology/wikiPageID
|
19073358
|
| http://dbpedia.org/ontology/wikiPageLength
|
3424
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1090662078
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Crohn%27s_disease +
, http://dbpedia.org/resource/Category:2000_establishments_in_Belgium +
, http://dbpedia.org/resource/Research_spin-off +
, http://dbpedia.org/resource/Katholieke_Universiteit_Leuven +
, http://dbpedia.org/resource/Euronext +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2000 +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Ghent_University +
, http://dbpedia.org/resource/The_Lancet +
, http://dbpedia.org/resource/Eduardo_Bravo +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_Belgium +
, http://dbpedia.org/resource/Category:Companies_based_in_Leuven +
, http://dbpedia.org/resource/Category:2018_mergers_and_acquisitions +
, http://dbpedia.org/resource/Takeda_Pharmaceutical_Company +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Belgium +
, http://dbpedia.org/resource/Leuven +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_disestablished_in_2018 +
, http://dbpedia.org/resource/Category:University_spin-offs +
|
| http://dbpedia.org/property/foundation
|
2000
|
| http://dbpedia.org/property/homepage
|
http://www.tigenix.com +
|
| http://dbpedia.org/property/id
|
BAyKY21aGQQ
, LEBtZ7rvnvo
, 1
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Biotechnology +
|
| http://dbpedia.org/property/keyPeople
|
Eduardo Bravo, CEO
|
| http://dbpedia.org/property/location
|
Leuven, Belgium
|
| http://dbpedia.org/property/name
|
TiGenix NV
|
| http://dbpedia.org/property/numEmployees
|
70
|
| http://dbpedia.org/property/title
|
TiGenix at Alliance for Regenerative Medicine meeting, March 2015
, TiGenix on Kanaal Z television
, Kanaal Z report, July 2014
|
| http://dbpedia.org/property/type
|
Public
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_company +
, http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:YouTube +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2000 +
, http://dbpedia.org/resource/Category:2000_establishments_in_Belgium +
, http://dbpedia.org/resource/Category:Biotechnology_companies_of_Belgium +
, http://dbpedia.org/resource/Category:Companies_based_in_Leuven +
, http://dbpedia.org/resource/Category:University_spin-offs +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_disestablished_in_2018 +
, http://dbpedia.org/resource/Category:2018_mergers_and_acquisitions +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Company +
|
| http://www.w3.org/2004/02/skos/core#closeMatch
|
http://www.grid.ac/institutes/grid.476221.4 +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/TiGenix?oldid=1090662078&ns=0 +
|
| http://xmlns.com/foaf/0.1/homepage
|
http://www.tigenix.com +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/TiGenix +
|
| http://xmlns.com/foaf/0.1/name
|
TiGenix NV
|
| owl:sameAs |
http://www.wikidata.org/entity/Q5363480 +
, http://dbpedia.org/resource/TiGenix +
, http://rdf.freebase.com/ns/m.04jk8r4 +
, http://yago-knowledge.org/resource/TiGenix +
, https://global.dbpedia.org/id/4jpnx +
|
| rdf:type |
http://dbpedia.org/class/yago/YagoPermanentlyLocatedEntity +
, http://dbpedia.org/ontology/Company +
, http://dbpedia.org/class/yago/WikicatCompaniesListedOnTheEuronextExchanges +
, http://dbpedia.org/class/yago/Institution108053576 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/SocialGroup107950920 +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q43229 +
, http://www.wikidata.org/entity/Q4830453 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://dbpedia.org/ontology/Agent +
, http://dbpedia.org/class/yago/WikicatBiotechnologyCompaniesOfBelgium +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
, http://dbpedia.org/class/yago/Company108058098 +
, http://www.wikidata.org/entity/Q24229398 +
, http://dbpedia.org/class/yago/Group100031264 +
, http://dbpedia.org/class/yago/Organization108008335 +
, http://dbpedia.org/ontology/Organisation +
|
| rdfs:comment |
TiGenix is a European cell therapy company … TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University.versiteit Leuven and the Ghent University.
|
| rdfs:label |
TiGenix
|
